Advertisement

© 2014

The Multiple Therapeutic Targets of A20

  • Christiane Ferran

Benefits

  • Reviews the modulation of anti-viral and immune responses by A20

  • Examines the biology of A20 binding partners

  • Discusses A20's involvement in tumor development and response to chemotherapies

Book

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 809)

Table of contents

  1. Front Matter
    Pages i-xxi
  2. Lynn Verstrepen, Isabelle Carpentier, Rudi Beyaert
    Pages 13-31
  3. Karine Enesa, Paul Evans
    Pages 33-48
  4. Meztli Arguello, Suzanne Paz, Christiane Ferran, Herwig P. Moll, John Hiscott
    Pages 49-64
  5. Cleide Gonçalves da Silva, Darlan Conterno Minussi, Christiane Ferran, Markus Bredel
    Pages 65-81
  6. Fiona C. McGillicuddy, Herwig P. Moll, Samira Farouk, Scott M. Damrauer, Christiane Ferran, Muredach P. Reilly
    Pages 83-101
  7. Gabor Bodonyi-Kovacs, Terry B. Strom, Prabhakar Putheti
    Pages 103-116
  8. Cleide Gonçalves da Silva, Jesus Revuelta Cervantes, Peter Studer, Christiane Ferran
    Pages 117-139
  9. Nathan W. Zammit, Shane T. Grey
    Pages 141-162
  10. Alessandra Mele, Jesus Revuelta Cervantes, Victor Chien, David Friedman, Christiane Ferran
    Pages 163-183
  11. Back Matter
    Pages 185-188

About this book

Introduction

This book is meant to provide the most current knowledge regarding the mechanisms of action of A20, if its versatile functions and their validation in animal models of human disease and its promise as a diagnostic biomarker and therapeutic target.

Keywords

NF-KB inhibitory function apoptosis diagnostic biomarker endothelial cells inflammation

Editors and affiliations

  • Christiane Ferran
    • 1
    • 2
  1. 1.Department of Surgery, Division of Vascular and Endovascular SurgeryCenter for Vascular Biology ResearchBostonUSA
  2. 2.The Transplant InstituteBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA

About the editors

Christiane Ferran, born in Beirut Lebanon, is Professor of Surgery at Harvard Medical School, Boston, Massachusetts, United States of America. She also holds an appointment as Staff Physician in the Division of Nephrology, Department of Medicine and as a Principal Research Investigator in the Division of Vascular Surgery at the Beth Israel Deaconess Medical Center (BIDMC). At BIDMC, Dr. Ferran is an active senior member of the Center for Vascular Biology Research, where she served as the chair of the Junior Faculty Mentoring Committee and of the Transplant Institute. She also chairs the Affinity Research Collaborative, an initiative aimed at fostering collaborative, interdisciplinary research program in the Department of Surgery. Main research interests include deciphering the physiologic molecular response to inflammation and how this response impacts disease pathophysiology, namely vascular diseases, allograft rejection, liver and islet regenerative processes and cellular metabolism. For the past two decades, this endeavor has mainly focused on the potent NF‑kB inhibitory protein, A20, for which she has continuously received external funding, starting in 1996 with a National Institutes of Health (NIH) funded RO1 aimed at studying the role of A20 in endothelial cell biology. Dr. Ferran is a member of numerous National and International Scientific Societies, including the American Society of Transplantation, the International Society of Transplantation, the American Society of Nephrology, the French Society of Nephrology and the American Society of Vascular Surgery. She has served as scientific reviewer on many National Institutes of Health (NIH), juvenile diabetes Research Foundation (JDRF) and Roche Organ Transplant Research Foundation (ROTRF) study sections.

Bibliographic information

Industry Sectors
Biomedicine
Biotechnology
Health & Hospitals
Pharma